Clinical Trials Browser

Lymphoma, Extranodal NK-T-Cell

Ovarian Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Cholangiocarcinoma

Biliary Tract Neoplasms

Urinary Bladder Neoplasms

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

Neoplasms, Pancreatic Neoplasms

Pancreatic Cancer Non-resectable

Dendritic Cell Sarcoma, Interdigitating

Ovarian Neoplasms

Pancreatic Cystic Neoplasm

Pancreatic Neoplasms

Lymphoma, Extranodal NK-T-Cell

Lung Diseases, Interstitial

Nasopharyngeal Carcinoma

Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Liver Neoplasms

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Nasopharyngeal Neoplasms

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

CLDN18.2 Positive

Hodgkin Disease

Urinary Bladder Neoplasms

Rhabdoid Tumor

Pancreatic cancer, adult

Non-Muscle Invasive Bladder Neoplasms

Advanced Squamous Non-Small Cell Lung Cancer

Non-Muscle Invasive Bladder Neoplasms

Breast Neoplasms, Recurrence

Pancreatic Neoplasms

Nasopharyngeal Neoplasms

Advanced Biliary Tract Cancer(BTC)

Nasopharyngeal Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Pancreatic Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Nasopharyngeal Carcinoma

Pancreatic Cancer Resectable

CLDN18.2-positive Advanced Biliary Tract Cancer

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Clinical Trials

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

HOPE-07-MIBC

REVIVE

RAINFOL-02

Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations

GENE

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

NUMANTIA-2

Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

RAINFOL™-07

ERASE-Chemo

ResQ108B-PANC

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

ORIGIN2

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

TRIFECTA

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

CECYDE

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

NOBLE

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

BRIGHT

ATARI-PDAC

PTCA199-16

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

OHAI-NMIBC-01

No Acronym

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

LEFT-PANC

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma